Armata Pharmaceuticals Files 8-K

Ticker: ARMP · Form: 8-K · Filed: Aug 26, 2024 · CIK: 921114

Armata Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyArmata Pharmaceuticals, INC. (ARMP)
Form Type8-K
Filed DateAug 26, 2024
Risk Levellow
Pages3
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: 8-k, reporting

TL;DR

Armata Pharma filed a routine 8-K, no major news.

AI Summary

Armata Pharmaceuticals, Inc. filed an 8-K on August 26, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.

Why It Matters

This filing indicates standard corporate reporting activity for Armata Pharmaceuticals, Inc., without disclosing new material events or financial performance details.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not contain any new material information that would indicate a change in risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.

What is the exact name of the registrant?

The exact name of the registrant is Armata Pharmaceuticals, Inc.

In which state was Armata Pharmaceuticals, Inc. incorporated?

Armata Pharmaceuticals, Inc. was incorporated in Washington.

What is the address of Armata Pharmaceuticals, Inc.'s principal executive offices?

The address of Armata Pharmaceuticals, Inc.'s principal executive offices is 5005 McConnell Avenue, Los Angeles, California 90066.

What is the business phone number listed for Armata Pharmaceuticals, Inc.?

The business phone number listed for Armata Pharmaceuticals, Inc. is (310) 655-2928.

Filing Stats: 824 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2024-08-26 07:50:05

Filing Documents

01

Item 7.01 Regulation FD Disclosure. Included as Exhibit 99.1 to this report is a copy of a poster presentation (the " Poster Presentation ") that Armata Pharmaceuticals, Inc. (the " Company ") expects to present at the 2024 Military Health System Research Symposium (the " Conference "), which is being held from August 26 to August 29, 2024, in Kissimmee, Florida. Investors should note that the Poster Presentation was printed prior to updated figures being available to the Company, and that the 75% figure in the following sentence in the Poster Presentation has subsequently increased to 80%: "~75% enrolled => Completion projected Q4 2024." On August 26, 2024, the Company issued a press release regarding its expected participation in the Conference, a copy of which is attached as Exhibit 99.2 hereto. The Company posted an updated corporate presentation dated August 26, 2024 (the " Corporate Presentation ") to its website at https://investor.armatapharma.com/events-and-presentations. The Corporate Presentation, which is furnished as Exhibit 99.3 hereto, replaces the corporate presentation dated August 16, 2024 previously posted to the Company's website. The Company plans to use its website to disseminate future updates to the Corporate Presentation and may not file or furnish a Current Report on Form 8-K alerting investors if the Corporate Presentation is updated. The information contained in the Poster Presentation and the Corporate Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (" SEC ") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, except as may be required by the federal securities laws, although it may do so from time to time as its management believes is warranted. Any such updating may

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Poster Presentation. 99.2 Press Release, dated August 26, 2024. 99.3 Corporate Presentation. 104 Cover Page Interactive Data File (embedded within XBRL document) - 2 -

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 26, 2024 Armata Pharmaceuticals, Inc. By: /s/ David D. House Name: David D. House Title: Senior Vice President, Finance and Principal Financial Officer - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing